Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.
Siyi WangXiaoyan YangJie HuangShuang YangQian WuHonghui ChenShuting WuChanglin DouGuo-Ping YangYuxia XiangPublished in: Expert opinion on investigational drugs (2022)
www.clinicaltrials.gov identifier is NCT04973722.